Series A Round

FOXO Technologies Inc. leverages AI-driven bioinformatics and microarray technologies to develop and commercialize epigenetic biomarkers of health and aging, focusing on longevity science and its applications in life insurance. This funding round will support the expansion of their innovative solutions aimed at enhancing the understanding of health and longevity. The company aims to revolutionize the life insurance industry by providing insurers with advanced tools to assess risk based on biological data. The Series A funding will also facilitate the development of new partnerships and collaborations within the health and insurance sectors, further driving innovation in longevity science.